Ticagrelor for the treatment of acute coronary syndromes

  • Technology appraisal guidance
  • TA236
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by the Liverpool Reviews and Implementation Group (LRiG):

  • Bagust A, Boland A, Blundell M et al. Ticagrelor for the treatment of acute coronary syndromes, February 2011

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I and II also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • AstraZeneca

II Professional/specialist and patient/carer groups:

  • Action Heart

  • British Cardiovascular Intervention Society (BCIS)

  • British Cardiovascular Society

  • British Heart Foundation

  • Heart Care Partnership (UK)

  • HEART UK

  • Royal College of Nursing

  • Royal College of Physicians

  • South Asian Health Foundation

III Other consultees:

  • Department of Health

  • NHS Bradford and Airedale

  • Oxfordshire PCT

  • Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bristol-Myers Squibb

  • British National Formulary

  • British Society for Cardiovascular Research

  • Commissioning Support Appraisals Service

  • Daiichi Sankyo

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Eli Lilly

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • Sanofi-Aventis

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on ticagrelor by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Nick Curzen, nominated by the Royal College of Physicians - clinical specialist

  • Professor Anthony Gershlick, Consultant Cardiologist, University Hospitals of Leicester, nominated by the Royal College of Physicians, Consultant Cardiologist, Southampton University Hospitals - clinical specialist

  • Liz Clark, nominated by the Heart Care Partnership - patient expert

  • John Miller, nominated by the Heart Care Partnership - patient expert

D The following individuals were nominated as NHS Commissioning experts by the selected PCT allocated to this appraisal. They gave their expert/NHS commissioning personal view on ticagrelor by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Greg Fell, Consultant in Public Health, NHS Bradford and Airedale selected by NHS Bradford and Airedale – NHS Commissioning expert

E Representatives from the following manufacturer/sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AstraZeneca